EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorUMC Utrecht
About this trial
Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora cavernosa, and the penile bulb for erectile function preservation.
Eligibility criteria
Qualifiers
Age ≥18 years
Histologically proven adenocarcinoma of the prostate
Low-risk or intermediate-risk prostate cancer according to NCCN risk categories (low risk: T1c-T2a, Gleason score ≤6, and PSA <10 µg/L; intermediate risk: T2b-T2c or Gleason score 7 or PSA 10-20 µg/L)
Patients with pT1a/b tumor diagnosis after transurethral resection of the prostate (TURP)
Disqualifiers
Use of (neo-)adjuvant androgen deprivation therapy
High-risk prostate cancer according to NCCN risk categories (T3a or Gleason score 8-10 or PSA >20 µg/L)
Patients with "bulky" iT3 tumor diagnosis
Previous pelvic irradiation or radical prostatectomy
Trial design
Treatments tested in this trial
- Neurovascular-sparing
Treatment groups
70 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov